Biogen's recent FDA approval for an Alzheimer's disease (AD) drug is arguably the biggest news this week in the healthcare industry. Both Biogen's and its development partner Eisai's stock prices...
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)